Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster Presentation at the American Association for the Study of ...
October 01 2013 - 2:00PM
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical
company engaged in the discovery and development of drugs for the
treatment of human viral diseases, today announced a poster
presentation featuring preclinical data for its uridine nucleotide
prodrug candidate for the treatment of hepatitis C virus (HCV)
infection at the 64th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD), which will take place in
Washington, DC, November 1-5, 2013. Full abstracts can now be
viewed at the AASLD website at www.aasld.org.
The following abstract will be presented in a poster session
during the AASLD Annual Meeting in the Poster Hall on Saturday,
November 2, 2013, 2:00pm – 7:30pm Eastern Time:
- Abstract No. 485: "A Novel Uridine Nucleotide Prodrug,
IDX20963, and Its Potential for Use in a Low-Dose Direct-Acting
Antiviral Regimen for HCV."
ABOUT HEPATITIS C
Hepatitis C virus is a common blood-borne pathogen infecting
three to four million people worldwide annually. The World
Health Organization (WHO) estimates that more than 170 million
people worldwide are chronically infected with HCV, representing a
nearly 5-fold greater prevalence than human immunodeficiency
virus.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical Company engaged in the
discovery and development of drugs for the treatment of human viral
diseases. Idenix's current focus is on the treatment of
patients with hepatitis C infection. For further information
about Idenix, please refer to www.idenix.com.
CONTACT: Idenix Pharmaceuticals Contact:
Teri Dahlman, (617) 995-9807
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024